Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sweta Parker"'
Autor:
Shramana M. Banerjee, Soha El-Sheikh, Anmol Malhotra, Charles A. Mosse, Sweta Parker, Norman R. Williams, Alexander J. MacRobert, Rifat Hamoudi, Stephen G. Bown, Mo R. S. Keshtgar
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 2, p 483 (2020)
Photodynamic therapy (PDT) is a technique for producing localized necrosis with light after prior administration of a photosensitizing agent. This study investigates the nature, safety, and efficacy of PDT for image-guided treatment of primary breast
Externí odkaz:
https://doaj.org/article/f7e27c823a514674bc7df0e6fcf8adec
Autor:
Rifat Hamoudi, Shramana Banerjee, Anmol Malhotra, Alexander J. MacRobert, Sweta Parker, Mo Keshtgar, Norman R. Williams, Soha El-Sheikh, Stephen G. Bown, Charles A. Mosse
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 2, p 483 (2020)
Journal of Clinical Medicine
Volume 9
Issue 2
Journal of Clinical Medicine
Volume 9
Issue 2
Photodynamic therapy (PDT) is a technique for producing localized necrosis with light after prior administration of a photosensitizing agent. This study investigates the nature, safety, and efficacy of PDT for image-guided treatment of primary breast
Autor:
Norman R. Williams, Rifat Hamoudi, Soha El Sheikh, Sweta Parker, Sandy MacRobert, Sandy Mosse, Mo Keshtgar, Shramana Banerjee, Stephen G. Bown, Anmol Malhotra
Publikováno v:
17th International Photodynamic Association World Congress.
Primary breast cancer while increasing in incidence has been successfully treated with a combination of surgery and adjuvant therapies in the majority of patients. Novel treatments for primary breast cancer need to show additional benefits to existin
Autor:
Elnaz Yaghini, Shramana Banerjee, Mark Neal, Sweta Parker, Soha El Sheikh, Mohammed Keshtgar, Alexander J. MacRobert
Publikováno v:
European Journal of Surgical Oncology (EJSO). 42:S24-S25
Autor:
Shramana Banerjee, M-a Tran-Dang, S Bown, Tim Davidson, A Malhotra, Keshtgar, Norman R. Williams, A Mosse, Soha El-Sheikh, D Tsukagoshi, Sweta Parker
Publikováno v:
Cancer Research. 77:OT2-02
Background: Photodynamic therapy (PDT) has been used to treat skin metastases from breast cancer. We investigated the use of PDT for the treatment of primary breast cancer. Trial design: Phase I/IIA, open label, non-randomised, single site, light dos
Autor:
Philip Ross, Peter Amlot, Pei-San Chan, Christopher McNamara, Alan G. Ramsay, T. Andrew Lister, Alessandra Malaroda, Surinder K. Sharma, John R. Buscombe, Anmol Malhotra, Shokri Othman, Richard H. J. Begent, John Violet, Gairin Dancey, Roslyn J. Francis, Nicholas Woodward, Sweta Parker, Alan J. Green, Natalie Griffin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(24)
Purpose: There is a need for new treatments for Hodgkin and T-cell lymphoma due to the development of drug resistance in a proportion of patients. This phase I study of radioimmunotherapy used CHT-25, a chimeric antibody to the α-chain of the interl
Autor:
Jimmy D. Bell, A Mayer, Geoff Boxer, Berend Tolner, Sweta Parker, Caroline J. Springer, Natalie Griffin, Richard H. J. Begent, Edward Grudus, Hassan Shahbakhti, Surinder K. Sharma, Duncan K. Wilkins, Kerry A. Chester, A J Green, R. J. Francis, Janet A Hartley
Publikováno v:
Cancer Research. 68:LB-200
Background: Antibody Directed Enzyme Prodrug Therapy (ADEPT) uses an antibody linked to an enzyme to deliver enzyme selectively to tumor deposits. When enzyme has localized to the tumor and cleared from the circulation, a low-toxicity prodrug is give
Autor:
Surinder K. Sharma, T. A. Lister, Pei-San Chan, A J Green, Christopher McNamara, Anmol Malhotra, Richard H. J. Begent, Ros Francis, Sweta Parker, Peter Amlot, Nicholas Woodward, Shokri Othman, John R. Buscombe, Peter G. Isaacson, John Violet, Natalie Griffin, Gairin Dancey
Publikováno v:
Blood. 110:648-648
The survival of patients with Hodgkin lymphoma (HL) has improved over recent decades due to advances in therapy and supportive care. The outcome for patients with relapsed or refractory disease, however, is still unsatisfactory. High dose therapy wit